Compare Cassava Sciences Inc (FLNA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard S&P 500 ETF — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Vanguard S&P 500 ETF trades at $689.59. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VOO | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $698.29 |
52-Week Low | $1.09 | $571.45 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
VOO trades at $690.59, down slightly by 0.07% with a bullish technical outlook supported by moving averages. The ETF tracks the S&P 500 index, providing diversified exposure to large-cap U.S. stocks. Recent news highlights strong investor interest in passive index investing, with multiple articles recommending Vanguard ETFs for long-term wealth building. Technical indicators show support at $686 and resistance at $696, with the overall signal leaning bullish.
As a passive index fund, VOO's performance mirrors the broader U.S. equity market. The primary opportunity lies in diversified market exposure with low costs, while risks include market volatility and economic headwinds. Recent dividend activity and positive market sentiment suggest continued institutional confidence in large-cap U.S. equities through this vehicle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
